GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. by Kitagawa, Kyoko et al.
RESEARCH Open Access
GSK3 regulates the expressions of human and
mouse c-Myb via different mechanisms
Kyoko Kitagawa1, Yojiro Kotake1, Yoshihiro Hiramatsu1,2, Ning Liu1, Sayuri Suzuki1, Satoki Nakamura3, Akira Kikuchi4,
Masatoshi Kitagawa1*
Abstract
Background: c-Myb is expressed at high levels in immature progenitors of all the hematopoietic lineages. It is
associated with the regulation of proliferation, differentiation and survival of erythroid, myeloid and lymphoid cells,
but decreases during the terminal differentiation to mature blood cells. The cellular level of c-Myb is controlled by
not only transcriptional regulation but also ubiquitin-dependent proteolysis. We recently reported that mouse c-
Myb protein is controlled by ubiquitin-dependent degradation by SCF-Fbw7 E3 ligase via glycogen synthase kinase
3 (GSK3)-mediated phosphorylation of Thr-572 in a Cdc4 phosphodegron (CPD)-dependent manner. However, this
critical threonine residue is not conserved in human c-Myb. In this study, we investigated whether GSK3 is involved
in the regulatory mechanism for human c-Myb expression.
Results: Human c-Myb was degraded by ubiquitin-dependent degradation via SCF-Fbw7. Human Fbw7
ubiquitylated not only human c-Myb but also mouse c-Myb, whereas mouse Fbw7 ubiquitylated mouse c-Myb but
not human c-Myb. Human Fbw7 mutants with mutations of arginine residues important for recognition of the CPD
still ubiquitylated human c-Myb. These data strongly suggest that human Fbw7 ubiquitylates human c-Myb in a
CPD-independent manner. Mutations of the putative GSK3 phosphorylation sites in human c-Myb did not affect
the Fbw7-dependent ubiquitylation of human c-Myb. Neither chemical inhibitors nor a siRNA for GSK3b affected
the stability of human c-Myb. However, depletion of GSK3b upregulated the transcription of human c-Myb,
resulting in transcriptional suppression of g-globin, one of the c-Myb target genes.
Conclusions: The present observations suggest that human Fbw7 ubiquitylates human c-Myb in a CPD-
independent manner, whereas mouse Fbw7 ubiquitylates human c-Myb in a CPD-dependent manner. Moreover,
GSK3 negatively regulates the transcriptional expression of human c-Myb but does not promote Fbw7-dependent
degradation of human c-Myb protein. Inactivation of GSK3 as well as mutations of Fbw7 may be causes of the
enhanced c-Myb expression observed in leukemia cells. We conclude that expression levels of human and mouse
c-Myb are regulated via different mechanisms.
Background
The leucine zipper transcription factor c-Myb is
expressed at high levels in immature progenitors of all
the hematopoietic lineages, and is essential for fetal liver
hematopoiesis, erythroid and myeloid bone marrow col-
ony formation, and T- and B-cell development [1-4].
Moreover, elevated c-Myb expression is associated with
hematological malignancies and has been reported in
many cases of acute myeloblastic and lymphoblastic
leukemias [1,5-7]. The keys to the control of c-Myb pro-
tein function are post-transcriptional modifications. The
c-Myb protein is phosphorylated by several kinases such
as MAPK, Nemo-like kinase (NLK) and glycogen
synthase kinase 3 (GSK3) [8-10]. It has been reported
that phosphorylation influences the activity and stability
of the c-Myb protein [11-17]. The stabilities of many
kinds of cellular proteins are often controlled by the
ubiquitin proteasome system, a rapid and selective
degradation mechanism in cells [18]. A previous study
indicated that the stability of c-Myb protein is also regu-
lated by this system. Especially, SCF-type E3 ubiquitin
ligases target various important cellular proteins
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including cell cycle regulators, oncogene and tumor sup-
pressor gene products [19,20]. Recently, we and another
group reported that the mouse c-Myb protein levels are
regulated by ubiquitin-dependent degradation via
SCF-Fbw7 E3 ligase in a phosphorylation-dependent
manner [21,22]. Fbw7 targets various proteins, including
cyclin E, Notch1, c-Myc, SREBP, c-Jun and SRC-3, for
ubiquitylation. These substrates contain a consensus
phospho-binding motif for Fbw7, termed the Cdc4
phosphodegron (CPD) [23]. Furthermore, we found that
mouse c-Myb Thr-572, which is located in a domain
equivalent to the CPD, is phosphorylated by GSK3,
thereby allowing recognition by Fbw7 and subsequent
promotion of ubiquitin-dependent degradation in the 26
S proteasome [22]. Regarding the regulatory system of
human c-Myb, it is unclear whether GSK3 is involved in
the control of human c-Myb stability, although we have
noticed that human c-Myb is also degraded by Fbw7. In
the present study, we analyzed the regions responsible
for human c-Myb ubiquitylation by SCF-Fbw7. We also
investigated whether repression of GSK3 affected the
stability and/or expression of human c-Myb. We found
that GSK3 is not involved in human c-Myb protein sta-
bility, but plays a role in its transcriptional suppression.
Materials and methods
Cell culture
HEK293 and HeLa cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum. K562 cells were maintained in
RPMI1640 supplemented with 10% fetal bovine serum.
Antibodies
The antibodies used in this study were anti-Myc anti-
body 9B11 (Cell Signaling), anti-Myc antibody 9E10
(Roche), anti-FLAG antibody M2 (Sigma), anti-HA
antibody 12CA5 (Roche), anti-c-Myb antibody 1-1
(UPSTATE), anti-Fbw7 antibody H-300 (Santa Cruz)
and anti-a-tubulin antibody DM1A (Sigma).
Plasmids
Complementary DNAs encoding mouse and human c-
Myb wild type and their mutants were cloned into
pcDNA3.1/Myc-His (Invitrogen) [22]. Expression plas-
mid of ubiquitin (pCGN-HA-Ub) was previously
described [24]. Expression plasmids of pCGN-HA-
human-Fbw7 and pcDNA3-FLAG-mouse-Fbw7a were
kindly provided by Keiichi Nakayama, Kyushu Univer-
sity. All deletion and point mutants of c-Myb were con-
structed using standard recombinant DNA techniques.
Immunoprecipitation
For immunoprecipitation (IP), cell lysates were incu-
bated with 2 μg of antibodies and protein G+ Sepharose
4FF (GE healthcare) at 4°C for 1 h. Immunocomplexes
were washed five times with lysis buffer. For double IP,
the first immunocomplexes, which were prepared with
anti-Myc antibody, were denatured by treatment with
SDS sample buffer at 100°C for 8 min. Then ubiquity-
lated c-Myb was immunoprecipitated again with anti-
Myc antibody. Immunoprecipitated samples as well as
the original cell lysates (input) were separated by
SDS-PAGE and transferred from the gel onto a PVDF
membrane (Millipore), followed by immunoblotting (IB).
Proteins were visualized using an enhanced chemilumi-
nescence system (Perkin Elmer).
In vivo ubiquitylation assay
All plasmids were transfected into HEK293 cells by the
calcium phosphate method. As described in previous
reports [22], to induce accumulation of polyubiquity-
lated c-Myb, cells were treated with the proteasome
inhibitor MG132 (20 μM), for 5 h starting at 43 h after
transfection and then harvested. Cell lysates were pre-
pared with lysis buffer (50 mM Tris-HCl, pH 7.5, 300
mM NaCl, 0.5% Triton X100, 10 μg/mL each of anti-
pain, pepstatin, E-64, leupeptin, and trypsin inhibitor
and 2.5 μg/mL of chymostatin) following IB analysis.
In vivo degradation assay
All plasmids were transfected into HeLa cells with the
use of Lipofectamine 2000 (Invitrogen). A total of 24 h
after transfection, each transfectant was divided into 5
culture dishes for the chase experiment, and after an
additional 24 h or 48 h, cells were treated with 12.5 μg/
mL of cycloheximide for the indicated times. Cell lysates
were subjected to immunoblotting. The intensity of the
bands was quantitated using image analysis software
Image Gauge 4.21 (Fujifilm), and the signal intensity of
each c-Myb was normalized using the individual levels
of a-tubulin.
GSK3 inhibitor treatment
At 48 h after transfection of the expression plasmids,
HeLa cells were cultured in the presence of 60 μM of 2-
thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole
(GSK3 inhibitor type II, Calbiochem), 30 μM of 3-(2,4-
dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-
2,5-dione (SB216763, Tocris) or dimethyl sulfoxide
(DMSO, vehicle control) for 24 h before treatment of
cycloheximide.
RNA interference
K562 cells were transfected with siRNA oligonucleotides
using HiPerFect transfection reagent (Qiagen) according
to the manufacturer’s protocol. At 48 h after transfec-
tion, cells were divided into two and subjected to IB and
QRT-PCR analysis. For the degradation assay, 6 h after
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transfection, each transfectant was divided into 4 culture
dishes. After 42 h additional hours, cells were treated
with 12.5 μg/mL of cycloheximide for the indicated
times. Cell lysates were subjected to IB. The nucleotide
sequences of siRNA for GSK3b was 5’- GUAAUCCAC-
CUCUGGCUAC -3’ with 3’ dTdT overhangs. It encodes
the same sequences that it was reported before [25].
Quantitative real time-PCR (QRT-PCR) analysis
Total RNA was isolated from cells with the use of Iso-
gen (Wako), and subjected to reverse transcription with
random hexanucleotide primers and SuperScript Reverse
Transcriptase II (Invitrogen). The resulting cDNA was
subjected to QRT-PCR using the Rotor-Gene 3000 sys-
tem (Corbett Research) and the SYBR premix Ex Taq
kit (TaKaRa). The amount of the transcripts of interest
was normalized against that of 18S rRNA as an internal
standard.
Statistical analysis
Statistical significance of differences was assessed with
t-test. A P value of < 0.05 was considered statistically
significant.
Results
Fbw7 promotes the degradation of human as well as
mouse c-Myb
We recently reported that mouse c-Myb is ubiquitylated
by SCF-Fbw7 E3 ligase in a phosphorylation-dependent
manner and degraded via a ubiquitin proteasome path-
way [22]. As shown in Figure 1A, human c-Myb also
bound to human Fbw7. To confirm whether the expres-
sion of human Fbw7 facilitates ubiquitin conjugation to
human c-Myb, we performed in vivo ubiquitylation
assays for the detection of HA-ubiquitin-modified c-
Myb using double immunoprecipitation. Since the first
immunoprecipitate may contain c-Myb and its asso-
ciated proteins, c-Myb was immunoprecipitated as the
only component in a second immunoprecipitation after
dissociation under denaturing conditions, and subjected
to immunoblotting with an anti-HA antibody to evalu-
ate the ubiquitylation of c-Myb itself. The results indi-
cated that Fbw7 promoted the ubiquitylation of human
c-Myb (Figure 1B). Furthermore, Fbw7 promoted the
degradation of human c-Myb (Figure 1C). These results
suggest that SCF-Fbw7 E3 ligase targets c-Myb for ubi-
quitin-dependent degradation in humans as well as in
mice.
Analysis of the human c-Myb domain required for
Fbw7-dependent ubiquitylation
In a previous study, we analyzed the regions of mouse
c-Myb responsible for its Fbw7-mediated ubiquityla-
tion and found that Thr-572 in mouse c-Myb is
phosphorylated by GSK3 for recognition by Fbw7,
which subsequently promotes ubiquitylation in a
phosphorylation-dependent manner [22]. However, it
is unclear whether GSK3 is also involved in the
control of human c-Myb stability. Thr-572 in mouse
c-Myb corresponds to a consensus motif for phos-
phorylation by GSK3 (Figure 2A). Fbw7 selectively
recognizes Thr-572 phosphorylated by GSK3 as a
putative CPD, and promotes ubiquitin-mediated pro-
teasomal degradation of mouse c-Myb (Figure 2A).
This phosphorylation site is substituted by alanine
(Ala-576) in human c-Myb, and consequently there is
only one putative CPD in the domain from Ser-560 to
Asp-564 (Figure 2A). Fbw7-dependent ubiquitylation
of mouse c-Myb was eliminated by substituting Thr-
572 with alanine (Figure 2B) or by deletion of the C-
terminal region, including Thr-572 (data not shown).
In contrast, neither deletion of the C-terminal region
of human c-Myb, which is equivalent to the critical
sequences in mouse c-Myb required for ubiquitylation
by Fbw7, nor alanine substitution of Ser-560 affected
its Fbw7-dependent ubiquitylation (Figure 2B, C).
Moreover, the human c-Myb mutant 13A, which has
substitutions of serine/threonine residues to alanine
residues in 13 C-terminal putative GSK3 phosphoryla-
tion sites, was still ubiquitylated and degraded in
an Fbw7-dependent manner (Figure 2B, D). We
attempted to identify the regions in human c-Myb
responsible for its Fbw7-mediated ubiquitylation.
Although we generated diverse deletion mutants of
human c-Myb and evaluated them by in vivo ubiquity-
lation assays, only two mutants with deletions in the
N-terminal region to amino acid (aa) 220 or 359 (Δ1-
220 and Δ1-359, respectively) completely lost Fbw7-
dependent ubiquitylation, while two other mutants
with a deletion in the N-terminal region to aa 104
(Δ1-104) or loss of 284 aa residues at the C-terminal
(Δ357) were markedly affected (Figure 2C). Subse-
quently, we prepared aa-substituted mutants with
mutations of the putative GSK3 phosphorylation sites
surrounding the N-terminal region (aa residues
23-220) or C-terminal region (aa residues 356-640). In
addition, we substituted Thr-235 or Thr-330 with ala-
nine, because these aa residues are potential GSK3
recognition consensus sequences but rarely conserved
between human and mouse c-Myb. All the examined
human c-Myb proteins with point mutations retained
the capacity for enhanced ubiquitylation by Fbw7
(Figure 2C). Based on these findings, we speculated
that the critical domains for Fbw7-dependent ubiqui-
tylation might be contained within aa residues 23-220
and/or 357-640. Although it remains unclear exactly
what roles these domains play, they are not likely to
be involved in GSK3-dependent phosphorylation.
Kitagawa et al. Cell Division 2010, 5:27
http://www.celldiv.com/content/5/1/27
Page 3 of 10
Figure 1 Fbw7-mediated ubiquitylation and stability control of human c-Myb protein. (A) Interaction between human c-Myb and human
Fbw7. HEK293 cells were transfected with Myc-tagged human c-Myb in the absence or presence of HA-tagged human Fbw7. Cell lysates were
subjected to immunoprecipitation (IP) with antibodies against HA, and the resulting precipitates as well as the original cell lysates (input) were
subjected to immunoblotting (IB) with antibodies against Myc or Fbw7. (B) HEK293 cells were transfected with expression constructs for Myc-
tagged human c-Myb with or without FLAG-tagged human Fbw7 and HA-tagged ubiquitin (Ub) as indicated. The cells were then incubated
with MG132. To precisely demonstrate the polyubiquitylation of c-Myb, cell lysates were subjected to double IP with antibodies against Myc or
mouse IgG. The resulting precipitates as well as the original cell lysates (input) and the first IP precipitates were subjected to IB with anti-HA,
anti-c-Myb or anti-FLAG antibodies. (C) HeLa cells were transfected with human c-Myb in the absence or presence of HA-human Fbw7. For the
cycloheximide (CHX) assay, cells were prepared after the indicated times of chase incubation and subjected to IB. The percentages of c-Myb
remaining after the various chase times were quantified by image analysis. The immunoblots shown are representative of four independent
experiments.
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Figure 2 Fbw7-dependent ubiquitylation of deleted or site-specific amino acid-substituted mutants of human c-Myb. (A) The consensus
motif for phosphorylation by GSK3 is indicated in the upper panel. The human c-Myb sequence is compared with that of mouse c-Myb
surrounding Thr-572, which is phosphorylated by GSK3 and then recognized by Fbw7, in the lower panel. Only one putative Cdc4-
phosphodegron (CPD) site in human c-Myb is described in parallel. (B) Fbw7-dependent ubiquitylation of mouse and human c-Myb mutants. For
analyses of mouse c-Myb ubiquitylation, HA-ubiquitin and Myc-tagged wild-type (WT) or mutant (T568A or T572A) mouse c-Myb in the absence
or presence of mouse Fbw7 were transfected into HEK293 cells. For analyses of human c-Myb ubiquitylation, HA-ubiquitin and WT or mutant
(Δ558, S560A or 13A) human c-Myb in the absence or presence of human Fbw7 were transfected into HEK293 cells. The transfected cells were
then incubated with MG132. Cell lysates were subjected to immunoblotting with an anti-Myc-tag antibody to detect ubiquitylation of the
mouse c-Myb protein or with an anti-c-Myb antibody to detect ubiquitylation of the human c-Myb protein. The results for the ubiquitylation of
the various mutant human c-Myb proteins by Fbw7 are summarized in (C). (C) Schematic representations of the human c-Myb mutants. The
asterisks and vertical bars indicate the putative GSK3 and NLK phosphorylation sites, respectively. DBS, DNA-binding sequence; TA, transactivation
domain; Leu Zipper, leucine zipper; NRD, negative regulatory domain. (D) Effects of mutations at the putative GSK3 recognition sites on Fbw7-
mediated degradation of c-Myb. HeLa cells were transfected with the human c-Myb mutant 13A in the absence or presence of HA-human
Fbw7. For the cycloheximide (CHX) assay, cells were prepared after the indicated times of chase incubation and subjected to immunoblotting.
The percentages of c-Myb remaining after the various chase times were quantified by image analysis.
Kitagawa et al. Cell Division 2010, 5:27
http://www.celldiv.com/content/5/1/27
Page 5 of 10
Human Fbw7 binds to and ubiquitylates c-Myb in a CPD-
independent manner, which is different from mouse
Fbw7
Although mouse Fbw7 required Thr-572, which is part
of the putative CPD motif in mouse c-Myb, human
Fbw7 did not require this residue. These observations
suggest the presence of different substrate recognition
mechanisms between human and mouse Fbw7. We
examined the binding and ubiquitylation abilities of
human Fbw7 for mouse c-Myb, and of mouse Fbw7 for
human c-Myb. We found that Fbw7 bound to c-Myb in
all the combinations examined (Figure 3A). Interest-
ingly, human Fbw7 was able to promote the ubiquityla-
tion of both human and mouse c-Myb, whereas mouse
Fbw7 was defective in its ability to ubiquitylate human
c-Myb (Figure 3B). We further addressed this issue
using arginine mutants of human Fbw7, R465C and
R505L, which were defective in binding to Notch and
promoting its degradation [26]. It is understood that
these mutation sites comprise the binding pocket of
Fbw7 that permits substrate recognition through contact
with phospho-Ser/Thr in the CPD sequence [26]. In this
study, we found that both mutants bound to human c-
Myb and also had the ability to ubiquitylate human c-
Myb as well as wild-type human Fbw7 (Figure 3C, D).
These findings suggest that human Fbw7 is able to bind
to and ubiquitylate c-Myb in a CPD-independent
manner.
Degradation of human c-Myb occurs in an Fbw7-
dependent but a GSK3-independent manner
We modified the cycloheximide (CHX) assay to investi-
gate the necessity of GSK3b activity for the degradation
of human c-Myb by Fbw7. GSK3 inhibitors (type II and
SB216763) did not inhibited the Fbw7-mediated degra-
dation of human c-Myb (Figure 4A). We also evaluated
the impact of SB216763 on K562 cells, and found that it
had no effect on the turnover of endogenous human c-
Myb (data not shown). To examine whether the abun-
dance of endogenous GSK3 affects the c-Myb stability,
we used RNAi to deplete GSK3b in K562 cells and per-
formed the CHX assay. The degradation of endogenous
human c-Myb was not affected by depletion of GSK3b
(Figure 4B). Taken together, we conclude that the degra-
dation of human c-Myb occurs in an Fbw7-dependent
but a GSK3-independent manner. Fbw7 may promote
the ubiquitin-dependent degradation of mouse and
human c-Myb via two distinct mechanisms.
Depletion of GSK3b promotes the transcription of human
c-Myb and represses the transcription of g-globin in K562
cells
We previously reported that depletion of Fbw7 mRNA
induces the accumulation of c-Myb protein without
changing its mRNA level in K562 cells [22]. In chase
assays, we noticed that depletion of GSK3b led to the
accumulation of human c-Myb protein, but did not
affect its stability (Figure 4B). We confirmed again that
human c-Myb protein was increased after depletion of
GSK3b in K562 cells (Figure 5A, B, C). Furthermore,
the c-Myb mRNA level was also significantly increased
after depletion of GSK3b in K562 cells (Figure 5D).
These findings suggest that GSK3 negatively regulates
Figure 3 Human Fbw7 mediates degradation of c-Myb via
binding and ubiquitylation, but each system is independent
and do not require the functional CPD. (A) Interaction between
human or mouse c-Myb and human or mouse Fbw7. HEK293 cells
were transfected with Myc-tagged c-Myb in the absence or
presence of Fbw7. Cell lysates were subjected to
immunoprecipitation (IP) with antibodies against HA or FLAG, and
the resulting precipitates as well as the original cell lysates (input)
were subjected to immunoblotting (IB) with antibodies against Myc
or Fbw7 which signal corresponded to arrowhead. Asterisk shows
non-specific signal. (B) Human or mouse Fbw7-dependent
ubiquitylation of mouse and human c-Myb. For analyses of c-Myb
ubiquitylation, HA-ubiquitin and Myc-tagged c-Myb in the absence
or presence of human or mouse Fbw7 were transfected into
HEK293 cells. The transfected cells were then incubated with
MG132. Cell lysates were subjected to IB with an anti c-Myb to
detect ubiquitylation of the c-Myb protein. Anti Fbw7 antibody was
used to detect Fbw7, which signal corresponded to arrowhead.
Asterisk shows non-specific signal. (C) Interaction between human
c-Myb and human WT or arginine mutant Fbw7. HEK293 cells were
transfected with human c-Myb in the absence or presence of FLAG-
tagged human Fbw7. Cell lysates were subjected to IP with
antibodies against FLAG, and the resulting precipitates as well as
the original cell lysates (input) were subjected to IB with antibodies
against c-Myb or FLAG. (D) Human Fbw7-dependent but arginine-
independent ubiquitylation of human c-Myb. For analyses of human
c-Myb ubiquitylation, HA-ubiquitin and human c-Myb in the
absence or presence of human WT or arginine mutant Fbw7 were
transfected into HEK293 cells. The transfected cells were then
incubated with MG132. Cell lysates were subjected to IB with an
anti c-Myb or anti FLAG to detect ubiquitylation of human c-Myb
protein or Fbw7, respectively.
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the transcription of the human c-Myb gene. It has been
reported that c-Myb inhibits g-globin gene expression in
K562 cells [27]. In the present study, we examined the
effects of ablation of GSK3b on c-Myb-dependent tran-
scriptional regulation by measuring the level of
endogenous g-globin expression by quantitative RT-PCR.
The abundance of g-globin transcripts was significantly
decreased after depletion of GSK3b (Figure 5E). These
results suggest that GSK3 controls the expressions of
c-Myb target genes via transcriptional suppression of
the c-Myb gene in human hematopoietic cells.
Discussion
GSK3 is one of the coregulators for turnover of several
Fbw7 substrates, including cyclin E, c-Jun, Myc, SREBP,
Notch, SRC and mouse c-Myb, which have the conserved
phospho-epitope known as the CPD [22,26,28-36]. GSK3
phosphorylates the central threonine or serine of the
CPD in each substrate. This phosphorylation of the CPD
is important for recognition and subsequent degradation
by Fbw7. In some cases, the substrates have mutations
within their CPDs, resulting in escape from Fbw7-
mediated degradation [35,37]. Retroviral Jun proteins
contain mutation in their CPD, which result in the
Figure 4 Effects of GSK3 on human c-Myb degradation. (A)
Effects of GSK3 inhibitors on the stability of human c-Myb. Human
c-Myb was transiently expressed with or without human Fbw7 in
HeLa cells. The cells were treated with a GSK3 inhibitor, type II or
SB216763, or DMSO for 24 h. The cells were then further treated
with cycloheximide (CHX) at the indicated times of chase
incubation and harvested. (B) Effects of depletion of GSK3b on the
stability of human c-Myb protein. K562 cells were transfected with
an siRNA for GSK3b or a control siRNA. At 48 h after transfection,
the CHX assay was performed.
Figure 5 Depletion of endogenous GSK3b affects the
transcriptional expression of human c-Myb and promotes the
transrepression of g-globin in K562 cells. K562 cells were
transfected with an siRNA for GSK3b or a control siRNA. At 48 h
after transfection, the protein levels of GSK3b and c-Myb were
analyzed by immunoblotting (A, B, C) and the mRNA levels of c-
Myb and g-globin were measured by quantitative RT-PCR (D, E). The
immunoblots in (A) show representative data. Each relative protein
or mRNA level was calculated as the mean ± s.d. from six
independent experiments.
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acquisition of resistance to Fbw7-dependent degradation
[38]. These mutations may contribute to increases in
their oncogenic characters. Notch-activated mutations
are frequently found in T-cell acute lymphoblastic leuke-
mias (T-ALL). A point mutation at Thr-2512 surround-
ing the CPD in Notch has been reported as one of the
mutation hotspots, and is predicted to abrogate Fbw7
binding [35]. Because the CPDs in Fbw7 substrates play
important roles for turnover, it is reasonable for them to
be highly conserved across species. Nevertheless, the
CPD in mouse c-Myb is not retained in human c-Myb
because the equivalent aa residue to Thr-572 in the
mouse c-Myb CPD is substituted by an alanine residue in
human c-Myb (Figure 2A).
Human Fbw7 ubiquitylated not only human c-Myb
but also mouse c-Myb, whereas mouse Fbw7 ubiquity-
lated mouse c-Myb but not human c-Myb. These find-
ings suggest that human Fbw7 recognizes c-Myb in a
different manner from mouse Fbw7. Two arginine
mutants (R465C and R505L) of human Fbw7, which are
mutated in arginine residues required for recognition of
the CPD in Notch, as another substrate of Fbw7 [26],
still bound to and ubiquitylated human c-Myb. There-
fore, human Fbw7 does not require either Arg-465 or
Arg-505 in the b-propeller fold for targeting of c-Myb
protein as a substrate. These findings are consistent
with the observation that the critical threonine residue
(Thr-572) in mouse c-Myb for human Fbw7-dependent
ubiquitylation is not conserved in human c-Myb.
Although further structural analyses are required to
fully resolve the recognition mechanism of human Fbw7
for c-Myb, our data strongly suggest that human Fbw7
ubiquitylates human c-Myb in a CPD-independent
manner.
Meanwhile, it has been proposed that Fbw7 binds to
and ubiquitylates cyclin E under two kinds of condi-
tions, namely monomeric or dimeric conformations,
which depend on the phosphorylation status of cyclin E
containing two CPD sites [19,39]. There may be some
variety in the substrate recognition mechanism of E3.
Corradini et al. [10] suggested that the PI3K/Akt/
GSK3b pathway is involved in the stability of human
c-Myb, and found increased stabilities of two c-Myb
deletion mutants (Δ(358-452) and Δ(389-418)) com-
pared with wild type c-Myb, although the corresponding
E3 ligase or phosphorylation sites were not identified.
More phosphorylation sites and/or multiple kinases may
be needed for the degradation of human c-Myb. Kanei-
Ishii et al. [21] reported that the mouse c-Myb/Fbxw7
interaction was enhanced by NLK, whose recognition
site (S/T-P) is also part of a consensus motif for GSK3
phosphorylation. We cannot exclude the possibility that
NLK may partially contribute to the recognition of
human c-Myb by Fbw7, although substitutions of the S/
T-P sites to alanine or C-terminal deletion mutants that
lacked some putative NLK sites did not influence the
ubiquitylation ability of Fbw7 (Figure 2C, T354A,
S560A, 13A, Δ498 and Δ361-497).
Elevated c-Myb expression has been reported in many
cases of acute myeloblastic and lymphoblastic leukemias
[6,7]. There are several possible mechanisms underlying
such increases. The first is gene amplification of c-Myb,
the second is enhancement of c-Myb protein stability
caused by a defect in Fbw7 resulting from a gene muta-
tion, and the third is facilitation of gene transcription of
c-Myb. Practically, there have been some reports of
c-Myb gene amplification cases and frequent Fbw7 gene
mutations in T-ALL [40,35]. In this study, we found
that GSK3 repressed the transcription of human c-Myb
mRNA. GSK3 participates in cell cycle regulation and is
a downstream target of the PI3K/Akt pathway, which
inhibits GSK3 through phosphorylation of Ser-9. The
PI3K/Akt pathway is activated by several kinds of
growth factors. Therefore, growth factor stimuli sup-
press GSK3 activity via PI3K/Akt, and this may lead to
enhance c-Myb expression. This mechanism is sup-
ported by our findings that depletion of GSK3 augmen-
ted c-Myb expression and repressed g-globin expression.
Alternatively, gene amplifications of PI3K have been
reported in human cancer [41]. It is possible that inacti-
vation of GSK3 via accelerated PI3K activity leads to the
induction of c-Myb transcription in leukemia. Kohmura
et al. [42] reported that the p38 MAPK and ERK path-
ways are involved in the differentiation of K562 cells
induced by STI571, a specific tyrosine kinase inhibitor
of Abl kinase. The expression level of c-myb mRNA was
clearly downregulated in K562 cells after incubation
with STI571. Their findings and the present results sug-
gest that kinase activity regulates cellular differentiation
through the transcriptional repression of human c-Myb.
To investigate whether GSK3 also regulates the tran-
scription of mouse c-Myb, we examined its influence on
mouse c-Myb expression using GSK3 inhibitors. The
results revealed that GSK inhibitors did not affect the
transcriptional regulation of mouse c-Myb (data not
shown). Moreover, we tried to confirm these results by
GSK3 knockdown using mouse cell line (M-1), in which
c-Myb expression was detected. However, we were
unable to achieve sufficient knockdown of GSK3 for
such evaluations in these cells. The species-specificity of
the Fbw7 operating mechanism does appear to be an
intriguing issue. However, the transcriptional regulation
of c-Myb by GSK3 cannot presently be concluded to be
a human-specific event.
c-Myb is abundantly expressed in immature erythroid
progenitor cells, and is reduced as the cells mature. It
has been observed that GATA-1, one of the erythroid
lineage-specific transcriptional factors, represses c-Myb
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transcription through GATA-1-binding sites in the
c-Myb promoter during erythroid differentiation [43].
GATA-1 activity is regulated by post-translational sys-
tems, which include a nuclear translocation process
[44]. Hyperphosphorylated GATA-1 protein is preferen-
tially found in the nucleus and has an enhanced DNA-
binding capacity [44,45]. Phosphorylation of GATA-1
may also have other functions, such as modulation of
the binding site preferences or interactions with other
transcriptional regulators. GATA-1 is phosphorylated in
vivo on seven serine residues [46]. Towatari et al. [47]
identified MAPK as one of the kinases that acts on
GATA-1, and further identified Ser-26 and Ser-178 as
the phosphorylation sites for MAPK. Zhao et al. [48]
identified the PI3K/AKT signaling pathway as a media-
tor of erythropoietin-induced phosphorylation of
GATA-1 at Ser-310, resulting in enhancement of its
transcriptional activity. They also found that the effects
of AKT during the program of erythroid maturation
were not limited to phosphorylation of Ser-310, and
described that AKT or other PI3K-dependent kinases
may phosphorylate additional sites on GATA-1. It is not
yet known whether GSK3 participates in the control of
GATA-1 activity. Further studies are required to eluci-
date the roles of kinases in the modulation of GATA-1.
Conditional inactivation of Fbw7 leads to the develop-
ment of lymphoma and T-ALL in mice [49-51]. It appears
that Fbw7 E3 ligase preferentially targets the regulators of
hematopoiesis, such as c-Myc and Notch, which interact
with Fbw7 in the GSK3-mediated phosphorylated form.
Therefore, GSK3 as well as Fbw7 is important controller
of the c-Myb, c-Myc and Notch protein levels for appro-
priate and sequential maturation of hematopoietic cells.
Although it has not yet been discussed whether the GSK3
activity changes in patients with leukemia, attenuation of
GSK3 activity may have a pleiotropic influence on leuke-
mia progression through the transcriptional and post-tran-
scriptional regulation of c-Myb.
Conclusions
In the mouse c-Myb protein, GSK3 phosphorylates Thr-
572, leading to recognition by Fbw7 for the promotion
of ubiquitin-dependent degradation. Fbw7 also promotes
the ubiquitylation and proteasome-mediated degradation
of human c-Myb, while GSK3 is not involved. Alterna-
tively, GSK3 negatively regulates the transcriptional
expression of human c-Myb to enhance the transcription
of g-globin, a target gene of c-Myb. Therefore, GSK3
regulates the expressions of human and mouse c-Myb
via different mechanisms. Inactivation of GSK3 as well
as mutations of Fbw7 may be involved in the elevated
c-Myb expression observed with human leukemia
development.
Acknowledgements
We thank Drs. Keiichi I. Nakayama for providing plasmids, Chiharu Uchida,
Takayuki Hattori, Hayato Ihara and Toshiaki Oda for useful discussions, and
Mr. Tatsuya Kobayashi, Daisuke Ichikawa and Naohiro Takamoto for their
technical assistance. This work was supported in part by grants from the
Ministry of Education, Science, Sports, Culture and Technology of Japan (M.K
and K.K).
Author details
1Department of Biochemistry 1, Hamamatsu University School of Medicine,
Hamamatsu, Japan. 2Second Department of Surgery, Hamamatsu University
School of Medicine, Hamamatsu, Japan. 3Third Department of Internal
Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
4Department of Molecular Biology and Biochemistry, Graduate School of
Medicine, Osaka University, Suita, Japan.
Authors’ contributions
KK and MK conceived of the study and drafted the manuscript. KK and YH
performed the experiments. YK, YH, SS, NL, SN and AK participated in its
design and coordination. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 September 2010 Accepted: 21 November 2010
Published: 21 November 2010
References
1. Greig KT, Carotta S, Nutt SL: Critical roles for c-Myb in hematopoietic
progenitor cells. Semin Immunol 2008, 4:247-256.
2. Friedman A: Runx1, c-Myb, and C/EBPα couple differentiation to
proliferation or growth arrest during hematopoiesis. J Cell Biochem 2002,
86:624-629.
3. Emambokus N, Vegiopoulos A, Harman B, Jenkinson E, Anderson G,
Frampton J: Progression through key stages of haemopoiesis is
dependent on distinct threshold levels of c-Myb. EMBO J 2003,
22:4478-4488.
4. Lieu YK, Kumar A, Pajerowski AG, Rogers TJ, Reddy EP: Requirement of c-
myb in T cell development and in mature T cell function. Proc Natl Acad
Sci USA 2004, 101:14853-14858.
5. Vegiopoulos A, García P, Emambokus N, Frampton J: Coordination of
erythropoiesis by the transcription factor c-Myb. Blood 2006,
107:4703-4710.
6. Slamon DJ, Boone TC, Murdock DC, Keith DE, Press MF, Larson RA,
Souza LM: Studies of the human c-myb gene and its product in human
acute leukemias. Science 1986, 233:347-351.
7. Siegert W, Beutler C, Langmach K, Keitel C, Schmidt CA: Differential
expression of the oncoproteins c-myc and c-myb in human
lymphoproliferative disorders. Eur J Cancer 1990, 26:733-737.
8. Aziz N, Wu J, Dubendorff JW, Lipsick JS, Sturgill TW, Bender TP: c-Myb and
v-Myb are differentially phosphorylated by p42mapk in vitro. Oncogene
1993, 8:2259-2265.
9. Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, Nomura T, Ishitani T, Kishida S,
Kokura K, Kurahashi T, Ichikawa-Iwata E, Kim Y, Matsumoto K, Ishii S: Wnt-1
signal induces phosphorylation and degradation of c-Myb protein via
TAK1, HIPK2, and NLK. Genes Dev 2004, 18:816-829.
10. Corradini F, Cesi V, Bartella V, Pani E, Bussolari R, Candini O, Calabretta B:
Enhanced proliferative potential of hematopoietic cells expressing
degradation-resistant c-Myb mutants. J Biol Chem 2005, 280:30254-30262.
11. Lüscher B, Eisenman RN: Mitosis-specific phosphorylation of the nuclear
oncoproteins Myc and Myb. J Cell Biol 1992, 118:775-784.
12. Miglarese MR, Richardson AF, Aziz N, Bender TP: Differential regulation of
c-Myb-induced transcription activation by a phosphorylation site in the
negative regulatory domain. J Biol Chem 1996, 271:22697-22705.
13. Bies J, Nazarov V, Wolff L: Identification of protein instability determinants
in the carboxy-terminal region of c-Myb removed as a result of
retroviral integration in murine monocytic leukemias. J Virol 1999,
73:2038-2044.
Kitagawa et al. Cell Division 2010, 5:27
http://www.celldiv.com/content/5/1/27
Page 9 of 10
14. Bies J, Feiková S, Bottaro DP, Wolff L: Hyperphosphorylation and increased
proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr
protein phosphatases. Oncogene 2000, 19:2846-2854.
15. Bies J, Feiková S, Markus J, Wolff L: Phosphorylation-dependent
conformation and proteolytic stability of c-Myb. Blood Cells Mol Dis 2001,
27:422-428.
16. Aziz N, Miglarese MR, Hendrickson RC, Shabanowitz J, Sturgill TW, Hunt DF,
Bender TP: Modulation of c-Myb-induced transcription activation by a
phosphorylation site near the negative regulatory domain. Proc Natl
Acad Sci USA 1995, 92:6429-6433.
17. Pani E, Ferrari S: p38MAPKδ ontrols c-Myb degradation in response to
stress. Blood Cells Mol Dis 2008, 40:388-394.
18. Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 1998,
67:425-479.
19. Bosu DR, Kipreos ET: Cullin-RING ubiquitin ligases: global regulation and
activation cycles. Cell Div 2008, 3:7.
20. Skaar JR, Pagano M: Control of cell growth by the SCF and APC/C
ubiquitin ligases. Curr Opin Cell Biol 2009, 21:816-824.
21. Kanei-Ishii C, Nomura T, Takagi T, Watanabe N, Nakayama KI, Ishii S: Fbxw7
acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase
(NLK)-induced degradation. J Biol Chem 2008, 283:30540-30548.
22. Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, Shibata K,
Nakamura S, Kikuchi A, Kitagawa M: Fbw7 promotes ubiquitin-dependent
degradation of c-Myb: involvement of GSK3-mediated phosphorylation
of Thr-572 in mouse c-Myb. Oncogene 2009, 28:2393-2405.
23. Nakayama KI, Nakayama K: Ubiquitin ligases: cell-cycle control and cancer.
Nat Rev Cancer 2006, 6:369-381.
24. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I,
Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M,
Nakayama KI, Hatakeyama S: Targeted disruption of Skp2 results in
accumulation of cyclin E and p27Kip1, polyploidy and centrosome
overduplication. EMBO J 2000, 19:2069-2081.
25. Yamamoto H, Yoo SK, Nishita M, Kikuchi A, Minami Y: Wnt5a modulates
glycogen synthase kinase 3 to induce phosphorylation of receptor
tyrosine kinase Ror2. Genes Cells 2007, 12:1215-1223.
26. O’Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M,
Meijerink JP, Pieters R, Draetta G, Sears R, Clurman BE, Look AT: FBW7
mutations in leukemic cells mediate NOTCH pathway activation and
resistance to γ-secretase inhibitors. J Exp Med 2007, 204:1813-1824.
27. Jiang J, Best S, Menzel S, Silver N, Lai MI, Surdulescu GL, Spector TD,
Thein SL: cMYB is involved in the regulation of fetal hemoglobin
production in adults. Blood 2006, 108:1077-1083.
28. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ:
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7
ubiquitin ligase. Science 2001, 294:173-177.
29. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI: Human F-
box protein hCdc4 targets cyclin E for proteolysis and is mutated in a
breast cancer cell line. Nature 2001, 413:316-322.
30. Ye X, Nalepa G, Welcker M, Kessler BM, Spooner E, Qin J, Elledge SJ,
Clurman BE, Harper JW: Recognition of phosphodegron motifs in human
cyclin E by the SCFFbw7 ubiquitin ligase. J Biol Chem 2004,
279:50110-50119.
31. Nateri AS, Riera-Sans L, Da Costa C, Behrens A: The ubiquitin ligase
SCFFbw7 antagonizes apoptotic JNK signaling. Science 2004,
303:1374-1378.
32. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE:
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3
phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad
Sci USA 2004, 101:9085-9090.
33. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H,
Ishida N, Okumura F, Nakayama K, Nakayama KI: Phosphorylation-
dependent degradation of c-Myc is mediated by the F-box protein
Fbw7. EMBO J 2004, 23:2116-2125.
34. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW,
Ericsson J: Control of lipid metabolism by phosphorylation-dependent
degradation of the SREBP family of transcription factors by SCFFbw7. Cell
Metab 2005, 1:379-391.
35. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G,
Ferrando A, Aifantis I: The SCFFBW7 ubiquitin ligase complex as a tumor
suppressor in T cell leukemia. J Exp Med 2007, 204:1825-1835.
36. Wu RC, Feng Q, Lonard DM, O’Malley BW: SRC-3 coactivator functional
lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell
2007, 129:1125-1140.
37. Welcker M, Clurman BE: FBW7 ubiquitin ligase: a tumour suppressor at
the crossroads of cell division, growth and differentiation. Nature Rev
2008, 8:83-93.
38. Wei W, Jin J, Schlisio S, Haroer JW, Kaelin WG: The v-Jun point mutation
allows c-Jun to escape GSK3-dependent recognition and destruction by
the Fbw7 ubiquitin ligase. Cancer Cell 2005, 8:25-33.
39. Welcker M, Clurman BE: Fbw7/hCDC4 dimerization regulates its substrate
interactions. Cell Div 2007, 2:7.
40. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA,
Langerak AW, Montpellier LB, Walrafen P, Delattre O, Aurias A, Leblanc T,
Dombret H, Gewirtz AM, Baruchel A, Sigaux F, Soulier J: The C-MYB locus is
involved in chromosomal translocation and genomic duplications in
human T-cell acute leukemia (T-ALL), the translocation defining a new
T-ALL subtype in very young children. Blood 2007, 110:1251-1261.
41. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-
Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004,
30:193-204.
42. Kohmura K, Miyakawa Y, Kawai Y, Ikeda Y, Kizaki M: Different roles of p38
MAPK and ERK in STI571-induced multi-lineage differentiation of K562
cells. J Cell Physiol 2004, 198:370-376.
43. Bartunek P, Králová J, Blendinger G, Dvorák M, Zenke M: GATA-1 and c-myb
crosstalk during red blood cell differentiation through GATA-1 binding
sites in the c-myb promoter. Oncogene 2003, 22:1927-1935.
44. Briegel K, Bartunek P, Stengl G, Lim KC, Beug H, Engel JD, Zenke M:
Regulation and function of transcription factor GATA-1 during red blood
cell differentiation. Development 1996, 122:3839-3850.
45. Partington GA, Patient RK: Phosphorylation of GATA-1 increases its DNA-
binding affinity and is correlated with induction of human K562
erythroleukaemia cells. Nucleic Acids Res 1999, 27:1168-1175.
46. Crossley M, Orkin SH: Phosphorylation of the erythroid transcription
factor GATA-1. J Biol Chem 1994, 269:16589-16596.
47. Towatari M, Ciro M, Ottolenghi S, Tsuzuki S, Enver T: Involvement of
mitogen-activated protein kinase in the cytokine-regulated
phosphorylation of transcription factor GATA-1. Hematol J 2004,
5:262-272.
48. Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S: Erythropoietin
stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/
AKT signaling pathway. Blood 2006, 107:907-915.
49. Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Alborán IM,
Nakayama K, Nakayama KI: Conditional inactivation of Fbxw7 impairs cell-
cycle exit during T cell differentiation and results in
lymphomatogenesis. J Exp Med 2007, 204:2875-2888.
50. Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y,
Oguro H, Nitta E, Ito K, Miyamoto K, Yoshiwara H, Hosokawa K, Nakamura Y,
Gomei Y, Iwasaki H, Hayashi Y, Matsuzaki Y, Nakayama K, Ikeda Y, Hata A,
Chiba S, Nakayama KI, Suda T: Fbxw7 acts as a critical fail-safe against
premature loss of hematopoietic stem cells and development of T-ALL.
Gene Dev 2008, 22:986-991.
51. Aifantis I, Raetz E, Buonamici S: Molecular pathogenesis of T-cell
leukaemia and lymphoma. Nat Rev Immunol 2008, 8:380-390.
doi:10.1186/1747-1028-5-27
Cite this article as: Kitagawa et al.: GSK3 regulates the expressions of
human and mouse c-Myb via different mechanisms. Cell Division 2010
5:27.
Kitagawa et al. Cell Division 2010, 5:27
http://www.celldiv.com/content/5/1/27
Page 10 of 10
